Hydroxychloroquine-Induced Phospholipidosis - A Forgotten Complication of a Common Drug

Indian J Nephrol. 2024 Mar-Apr;34(2):175-177. doi: 10.4103/ijn.ijn_325_22. Epub 2023 Aug 4.

Abstract

Hydroxychloroquine (HCQ) has immunomodulatory and immunosuppressive properties and is used in many rheumatological conditions like systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's syndrome. It is usually a widely used and well-tolerated DMARD (Disease Modifying Anti Rheumatic Drugs). Its most feared toxicities include retinopathy and, rarely, cardiomyopathy. Among its other reported side effects is drug-induced phospholipidosis. Here, we report two cases of HCQ-induced phospholipidosis based on renal biopsy electron microscopy. HCQ-induced phospholipidosis, although uncommon, must be considered as one of the differentials in a patient with persistent proteinuria.

Keywords: Hydroxychloroquine; phospholipidosis; proteinuria.

Publication types

  • Case Reports

Grants and funding

Financial support and sponsorship